[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Ako J, Eto M, Kim S, Iijima K, Watanabe T, Ohike Y, Yoshizumi M, Ouchi Y: Pericardial constriction due to malignant lymphoma. Jpn Heart J; 2000 Sep;41(5):673-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial constriction due to malignant lymphoma.
  • We experienced a case of T-cell lymphoma demonstrating diastolic heart failure as an initial manifestation.
  • Clinical presentation was congestive heart failure and cervical lymphadenopathy.
  • Right heart catheterization revealed "dip and plateau" waveforms in right ventricular pressure, which suggested a constrictive nature of heart failure.
  • Gallium scintigram showed marked uptake in the heart.
  • Biopsy from a cervical lymph node confirmed the diagnosis of malignant lymphoma of T-cell origin.
  • Diastolic heart failure remained after successful chemotherapy.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma, T-Cell / complications. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132174.001).
  • [ISSN] 0021-4868
  • [Journal-full-title] Japanese heart journal
  • [ISO-abbreviation] Jpn Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Fujita Y, Ikebuchi M, Tarui S, Irie H: Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac operation and chemotherapy. Circ J; 2009 May;73(5):967-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac operation and chemotherapy.
  • A 56-year-old man, suffering from rapidly worsening general fatigue, dyspnea on exercise and epigastralgia, was referred for evaluation and treatment of a cardiac tumor.
  • Lymphoma was highly suggested.
  • The postoperative course was good, with cessation of right heart failure.
  • Pathological examination suggested malignant lymphoma, diffuse large B-cell type.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cardiac Surgical Procedures. Heart Neoplasms / drug therapy. Heart Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Heart Failure / drug therapy. Heart Failure / etiology. Heart Failure / surgery. Humans. Male. Middle Aged. Prednisone / administration & dosage. Rituximab. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088397.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


3. Cho JG, Ahn YK, Cho SH, Lee JJ, Chung IJ, Park MR, Kim HJ, Jeong MH, Park JC, Kang JC: A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci; 2002 Aug;17(4):549-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of secondary myocardial lymphoma presenting with ventricular tachycardia.
  • Malignant lymphoma can involve the cardiac cavity or myocardium as a mass.
  • Clinical symptoms of its cardiac involvement are usually absent or nonspecific, making the diagnosis of the cardiac involvement very difficult before death.
  • We experienced a patient with secondary myocardial non-Hodgkin's lymphoma presenting with sustained ventricular tachycardia (VT) as a primary clinical problem.
  • Physical examination revealed rapid heart beat with variable intensity of the first heart sound and soft mass in the lower abdomen.
  • Cytological examination of aspirated pericardial fluid and percutaneous needle biopsy of the abdominal mass revealed a diffuse large cell type non-Hodgkin's lymphoma.
  • Myocardial masses and ventricular tachycardia resolved with chemotherapy using cyclophosphamide, adriamycin, vincristine and prednisone regimen.
  • [MeSH-major] Heart Neoplasms / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Myocardium / pathology. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172054.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054895
  •  go-up   go-down


Advertisement
4. Saito T, Tamaru J, Kayao J, Kuzuu Y, Wakita H, Mikata A: Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report. Acta Cytol; 2001 Nov-Dec;45(6):1043-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report.
  • BACKGROUND: Primary malignant lymphoma of the heart is extremely rare.
  • Because its clinical signs and symptoms are typically nonspecific, it is often very difficult to detect cardiac involvement while the patient is alive.
  • We describe a case of malignant lymphoma involving predominantly the heart and pericardium and diagnosed by pericardiac effusion cytology antemortem.
  • Diagnosis of diffuse large B-cell lymphoma was made by cytomorphologic examination and flow cytometry of the tumor cells obtained from the effusion.
  • Although chemotherapy was instituted immediately, the patient died of progressive heart failure.
  • Diffuse large B-cell lymphoma predominantly involving the intracardiovascular region was confirmed at autopsy.
  • CONCLUSION: From the experience in this case, we conclude that cytopathologic examination of sonographically guided aspiration of the cardiovascular region is very useful for antemortem diagnosis of primary malignant lymphoma of the heart.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Echocardiography. Fatal Outcome. Female. Flow Cytometry. Heart Failure / etiology. Heart Failure / pathology. Humans. Immunophenotyping. Pericardial Effusion / diagnosis. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11726101.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Nakagawa Y, Ikeda U, Hirose M, Ubukata S, Katsuki TA, Kaminishi Y, Saito T, Hironaka M, Izumi T, Shimada K: Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab). Circ J; 2004 Feb;68(2):172-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab).
  • Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks.
  • Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule.
  • The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Gallium Radioisotopes. Humans. Immunohistochemistry. Male. Radionuclide Imaging. Remission Induction / methods. Rituximab. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14745155.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Gallium Radioisotopes; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


6. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs: Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica; 2002 Jan;87(1):67-77
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
  • BACKGROUND AND OBJECTIVES: Clinical and pathologic variability of post-transplant lymphoproliferative disorders (PTLDs), their aggressive behavior and the recognized therapy-related toxicity make management of patients with these disorders difficult.
  • Assessment of first-line treatment and identification of prognostic factors need to be better defined.
  • DESIGN AND METHODS: Data on 40 PTLDs which developed in adult solid organ recipients were analyzed in order to evaluate clinical and pathologic features, response to treatment and prognostic factors.
  • RESULTS: The median time from transplant to PTLD was 56 months.
  • Regarding histologic features, plasmacytic hyperplasia was diagnosed in 5 patients (12.5%), polymorphic lymphoproliferative disorders in 3 (7.5%), malignant lymphoma in 32 (80%).
  • The diagnosis was made at autopsy in eight patients (20%).
  • Twenty-nine patients completed their scheduled treatment and are evaluable for outcome.
  • The cumulative probability of survival at 1 year is 57% (CI 37.6-73.4) and the median survival time of the entire group has not been reached at 54 months.
  • Therapy tailored on histologic and clinical features of PTLD is feasible and is able to give long-lasting complete responses.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Female. Heart Transplantation / adverse effects. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori / isolation & purification. Herpesvirus 4, Human / isolation & purification. Humans. Immunocompromised Host. Interleukin-10 / blood. Kidney Transplantation / adverse effects. Life Tables. Liver Transplantation / adverse effects. Lung Transplantation / adverse effects. Male. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Factors. Rituximab. Survival Analysis. Survival Rate. Time Factors. Treatment Outcome. Viral Load

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801467.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 130068-27-8 / Interleukin-10; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Takenaka S, Mitsudo K, Inoue K, Goto T, Kadota K, Fujii S, Yamamoto H, Fuku Y, Hirono A, Tanaka H, Taba M, Ikeda A, Kojima Y, Maekawa J, Maekawa S, Takahashi N, Saeki H, Nakamura Y, Oonishi T, Ueda N: Successful treatment of primary cardiac lymphoma with atrioventricular nodal block. Int Heart J; 2005 Sep;46(5):927-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma with atrioventricular nodal block.
  • However, she developed shortness of breath 2 months after the implantation.
  • A diagnosis was made based on a CT scan and histology.
  • Although most primary cardiac malignant lymphomas are associated with a poor prognosis, the patient was treated successfully with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Block / complications. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Pacemaker, Artificial. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272785.001).
  • [ISSN] 1349-2365
  • [Journal-full-title] International heart journal
  • [ISO-abbreviation] Int Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


8. Tanoue K, Sanada J, Kayano T, Tanaka H, Terashi T: [Malignant lymphoma with various cardiac manifestations: a case report]. J Cardiol; 2002 Sep;40(3):117-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma with various cardiac manifestations: a case report].
  • A 49-year-old woman presented with malignant lymphoma manifesting as dyspnea, palpitation and leg edema.
  • The diagnosis was malignant lymphoma(B-cell) based on lymph node biopsy.
  • Chemotherapy(CHOP) was performed under a suspected diagnosis of cardiac invasion of malignant lymphoma.
  • Immediately after chemotherapy, ECG showed complete atrioventricular block with sinus arrest, ventricular fibrillation and atrial fibrillation.
  • ECG was normalized after 2 weeks on chemotherapy.
  • However, she died of recurrence of malignant lymphoma on day 116.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / pathology. Hypertrophy, Left Ventricular / etiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Electrocardiography. Female. Humans. Middle Aged. Neoplasm Invasiveness. Pericardial Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12325461.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Yokoyama S, Naito Y, Tei I, Koh E, Nagata A, Katoh G: [Primary cardiac malignant lymphoma diagnosed intraoperatively during aortic valve repair; report of a case]. Kyobu Geka; 2004 Nov;57(12):1131-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac malignant lymphoma diagnosed intraoperatively during aortic valve repair; report of a case].
  • The cardiac catheterization was showed moderate aortic regurgitation.
  • We have not noticed cardiac tumor at all until aortic valve replacement.
  • Postoperative pathological diagnosis of the tumor was malignant lymphoma.
  • The tumor had a characteristic architecture of a cardiac MICE (mesothelial/monocytic incidental cardiac excrescence).
  • After the operation, additional chemotherapy using doxorubicin and cysplatin was performed.
  • [MeSH-major] Aortic Valve Insufficiency / surgery. Heart Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aortic Valve / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Heart Valve Prosthesis Implantation. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553031.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Avilés A, Nambo MJ, Neri N, Talavera A, Castañeda C, Murillo E, Cleto S, Huerta-Guzmán J: Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma. Med Oncol; 2004;21(3):269-72
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
  • The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis.
  • Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed.
  • Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed.
  • The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):651-6 [7694634.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2282-8 [9610711.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3564-73 [8260695.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):339-47 [1824863.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1275-81 [8648384.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2916-23 [8523055.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 15456955.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Oshiro A, Nagasaki A, Nakachi A, Uchima N, Hasegawa H, Nakazato T, Nakamoto M, Kinjo N, Kinjo F, Taira N, Masuda M, Takasu N: [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1169-73
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy].
  • A 65-year-old woman with diabetes mellitus was hospitalized for heart failure and anemia in August 2001, and recovered with conservative treatment.
  • The diagnosis of a diffuse large B-cell lymphoma, clinical stage IIE, was made by endoscopic biopsy.
  • Although surgical resection of the localized intestinal tumor would have been a common choice for initial treatment, polychemotherapy was selected; the patient had diabetes mellitus and preferred polychemotherapy to surgical operation.
  • Because of bulky intestinal mass, transmural disease and sensitive histological type, standard-dose chemotherapy was considered to include a high risk of intestinal perforation.
  • We performed dose-escalating chemotherapy: A half dose of THP-COP (pirarubicin, cyclophosphamide, vincristine) was given at the start in October 2001, 60% THP-COP as the next cycle, 80% THP-COP as the 3rd cycle and thereafter.
  • Without serious complications of the intestine, she received a total of 6 cycles of chemotherapy and subsequent involved field radiation.
  • There has been no evidence of recurrence of disease 14 months from the start of chemotherapy.
  • When conditions make surgical treatment difficult, dose-escalating chemotherapy in a treatment cycle may be considered as an alternative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


12. Boccardi L, Pino PG: [Primary lymphoma of the right atrium: a case report]. Ital Heart J Suppl; 2004 Jun;5(6):487-91
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the right atrium: a case report].
  • Primary cardiac tumor is an extremely rare disease and is associated with a high mortality.
  • The cases described in the literature are recently increased thanks to the employment of the new diagnostic methodologies (computed tomography, nuclear magnetic resonance, transesophageal echocardiography).
  • Particularly the primitive lymphoma, non-HIV correlated, is very rare (< 1.5% of all cardiac tumors), but it is treatable when appropriately diagnosed.
  • The examination of the tissue obtained by transvenous intracardiac biopsy with transesophageal echocardiography guidance revealed high grade non-Hodgkin's lymphoma of B-cell lineage.
  • The patient achieved complete tumor remission after treatment with standard chemotherapy.
  • This case demonstrates that early diagnosis might contribute to a better prognosis for patients with malignant lymphoma of the heart.
  • [MeSH-major] Heart Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Therapy, Combination. Echocardiography, Doppler. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Heart Atria / pathology. Humans. Male. Middle Aged. Remission Induction. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15471154.001).
  • [ISSN] 1129-4728
  • [Journal-full-title] Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology
  • [ISO-abbreviation] Ital Heart J Suppl
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


13. Sturm A, Noppeney R, Reimer J, Ross B, Baumgart D, Sundermann T, Sadony V, Gerken G: [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Dtsch Med Wochenschr; 2001 Mar 30;126(13):364-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection].
  • HISTORY AND FINDINGS: A 35-year-old man who, as a result of intravenous drug abuse, had become infected with HIV 18 years previously, was admitted with signs of right-heart failure.
  • DIAGNOSIS, TREATMENT AND COURSE: Endocarditis with atrial thrombi and recurrent pulmonary emboli was diagnosed and treated with antibiotics and anticoagulants.
  • Computed tomography of skull, thorax and abdomen did not demonstrate any significantly enlarged lymph nodes.
  • Exploratory thoracotomy revealed an infiltrating highly malignant centroblastic non-Hodgkin's lymphoma (NHL) of almost the entire free wall of the right atrium.
  • After two courses of chemotherapy (CHOP protocol) the size of the tumour had significantly decreased.
  • CONCLUSION: The differential diagnosis of a right atrial tumour can be difficult in patients with HIV or AIDS.
  • Even if the site is atypical and there is no lymphadenopathy, a lymphoma should be considered.
  • In case of doubt a histological diagnosis via an exploratory thoracotomy should be performed.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Echocardiography, Transesophageal. Heart Atria / pathology. Humans. Male. Prednisone / administration & dosage. Substance Abuse, Intravenous / complications. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332231.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Murakami S, Terakado M, Misumi M, Tsuji Y, Okubo K, Hirayama R, Inoue K, Arai E: Situs inversus totalis with malignant lymphoma of the stomach: report of a case. Surg Today; 2003;33(7):533-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Situs inversus totalis with malignant lymphoma of the stomach: report of a case.
  • We report a case of situs inversus totalis with malignant lymphoma of the stomach, which was successfully treated by surgery followed by chemotherapy and irradiation.
  • Chest X-ray showed a right-sided heart, and ultrasonography and computed tomography (CT) of the abdomen showed a situs inversus totalis with multiple gallstones in the gallbladder.
  • Histopathological examination confirmed a diagnosis of malignant lymphoma of the stomach (diffuse large B-cell type) with metastasis to the regional lymph nodes.
  • Chemotherapy using the CHOP regimen was given three times, starting 1 month postoperatively.
  • At the time of writing, 10 months after surgery, the patient is well with no signs of recurrence and leading a normal life.
  • Careful preoperative assessment is very important for determining the most appropriate surgical procedure in patients with situs inversus totalis associated with a malignancy.
  • [MeSH-major] Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Situs Inversus / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Imaging, Three-Dimensional. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14507000.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Kragelund CB, Søndergaard L, Bjerrum OW: [Primary cardiac lymphoma]. Ugeskr Laeger; 2001 Feb 26;163(9):1289-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma].
  • Primary cardiac non-Hodgkin lymphoma is very rare.
  • Results recently published suggest that the prognosis is good, if the lymphoma is diagnosed early.
  • A myocardial biopsy showed malignant non-Hodgkin lymphoma of the diffuse, large cell B-type.
  • The patient was treated with chemotherapy and control MRI after four treatments showed complete regression of the tumour.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Female. Heart Atria / pathology. Heart Ventricles / pathology. Humans. Magnetic Resonance Imaging. Myocardium / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11258255.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Yukiiri K, Mizushige K, Ueda T, Kohno M: Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report. Angiology; 2001 Aug;52(8):563-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report.
  • A 76-year-old man was found to have esophageal squamous cell carcinoma and had been treated with radiational therapy and chemotherapy.
  • No findings indicated a recurrence of the esophageal cancer; cytologic studies showed malignant lymphoma cells of B-cell origin.
  • This is the first case of second primary cardiac B-cell lymphoma after combination therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Cisplatin / administration & dosage. Coronary Angiography. Echocardiography, Transesophageal. Esophagoscopy. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Pericardial Effusion / pathology. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11512697.001).
  • [ISSN] 0003-3197
  • [Journal-full-title] Angiology
  • [ISO-abbreviation] Angiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • Clinical symptoms of cardiac involvement are rare, explaining the usual post-mortem diagnosis.
  • The presentation of cardiac involvement by arrhythmias and conduction defects is very uncommon.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Electrocardiography. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Fresneau B, Oberlin O, Brugières L, Valteau-Couanet D, Patte C: [Malignant primary cardiac tumors in childhood and adolescence]. Arch Pediatr; 2010 May;17(5):495-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary cardiac tumors in childhood and adolescence].
  • Primary heart tumors are uncommon in children.
  • The majority of them are benign, with only 10% malignant.
  • Among malignant cardiac tumors, sarcoma (rhabdomyosarcoma, angiosarcoma, synovial sarcoma) and lymphoma (Burkitt's lymphoma, large B-cell lymphoma, lymphoblastic lymphoma) predominate.
  • There are few published pediatric series on malignant primary cardiac tumors.
  • We report here 3 observations of primary malignant cardiac tumors, 2 cases of sarcoma (angiosarcoma and synovial sarcoma) and 1 case of Burkitt's lymphoma.
  • A precise pathological diagnosis is necessary for the proper management of these patients.
  • For sarcoma, treatment associates surgery and chemotherapy.
  • Surgery should be as complete as possible because of the lack of chemotherapy sensitivity of some sarcomas, mainly angiosarcoma and synovial sarcoma.
  • Therefore, the prognosis of cardiac sarcoma remains poor.
  • For primary cardiac lymphoma, management should not be different from lymphoma in other locations.
  • Chemotherapy is the main treatment, and surgery has to be used only when complications occur.
  • Prognosis depends on histology and not lymphoma location, and so is better than the prognosis for sarcoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Diagnosis, Differential. Dyspnea / etiology. Echocardiography. Fatal Outcome. Female. Heart Atria / pathology. Heart Atria / surgery. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Pulmonary Heart Disease / diagnosis. Pulmonary Heart Disease / etiology. Superior Vena Cava Syndrome / diagnosis. Superior Vena Cava Syndrome / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20338733.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Fuchida S, Yamada N, Uchida R, Okano A, Okamoto M, Ochiai N, Shimazaki C: Malignant lymphoma presenting as a cardiac tumor and superior vena caval syndrome successfully treated by haploidentical stem cell transplantation. Leuk Lymphoma; 2005 Oct;46(10):1517-21
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma presenting as a cardiac tumor and superior vena caval syndrome successfully treated by haploidentical stem cell transplantation.
  • A 16 year-old male with B-cell non-Hodgkin's lymphoma presenting as a cardiac tumor and superior vena caval (SVC) syndrome received a haploidentical stem cell transplant (SCT) from his mother after conventional and salvage chemotherapy.
  • He received additional radiation therapy for the residual tumor and is alive and well on day 640 after transplantation.
  • Malignant lymphoma presenting as a cardiac tumor, including primary cardiac lymphoma, is rare.
  • Although many reports have shown the poor prognosis of cardiac lymphoma, our case suggests that allogeneic haploidentical SCT might be useful for the treatment of aggressive cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Stem Cell Transplantation. Superior Vena Cava Syndrome / complications. Superior Vena Cava Syndrome / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194899.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Elbl L, Chaloupka V, Vásová I, Nehyba S, Vorlícek J, Navrátil M, Kiss I, Cíhalová M: [Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas]. Vnitr Lek; 2000 Nov;46(11):768-75
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas].
  • The authors evaluated using clinical and echocardiographic examination the effect of chemotherapy involving bolus administration of doxorubicin on the heart muscle in 90 patients with non-Hodgkin lymphoma and with Hodgkin lymphoma.
  • In 18% of patients they found an asymptomatic decrease of the left ventricular ejection fraction during chemotherapy, chronic cardiotoxicity was recorded in 5% patients, in 2% of the patients one year after termination of chemotherapy a clinically latent myocardial infarction was found.
  • The diastolic function was impaired (impaired relaxation) in 44% patients after terminated chemotherapy and in 50% after one year.
  • Echocardiographic examination provided evidence that the impaired systolic and diastolic function persists even after one year following termination of chemotherapy.
  • High-dose chemotherapy with administration of peripheral stem cells did not lead to marked deterioration of left ventricular function as compared with patients who did not undergo this treatment.
  • The main clinical complications--death, cardiotoxicity, relapse of the malignant disease, cardiovascular complications--were present in the course of a 18.5-month follow up after establishment of the diagnosis in 32% of the patients.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Doxorubicin / adverse effects. Lymphoma / drug therapy. Ventricular Dysfunction, Left / chemically induced
  • [MeSH-minor] Adolescent. Adult. Aged. Echocardiography. Female. Heart / drug effects. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637892.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Tanaka J, Takamoto S, Ryu T, Ichikawa K, Masuo M, Saito T: [Primary cardiac lymphoma: a case report]. J Cardiol; 2002 Nov;40(5):225-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: a case report].
  • Transvenous biopsy failed to obtain sufficient specimens for the histological diagnosis.
  • The tumor progressed rapidly and heart failure was intractable.
  • The diagnosis was primary cardiac lymphoma on the basis of elevated soluble interleukin-2 receptor and solitary accumulation of gallium-67 in the heart.
  • Chemotherapy was immediately started.
  • After two courses of chemotherapy, the intracardiac tumor disappeared.
  • Needle biopsy disclosed diffuse B-cell non-Hodgkin's malignant lymphoma.
  • Early diagnosis and immediate chemotherapy are important for the treatment of primary cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Echocardiography. Female. Gallium Radioisotopes. Heart Failure / etiology. Humans. Magnetic Resonance Imaging. Receptors, Interleukin-2 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12463097.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Receptors, Interleukin-2
  •  go-up   go-down


22. Maeder M, Spieler P, Krapf R, Diethelm M: Cytologically malignant lymphoid pericardial effusion with benign clinical outcome. Swiss Med Wkly; 2005 Jun 25;135(25-26):377-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologically malignant lymphoid pericardial effusion with benign clinical outcome.
  • BACKGROUND: Isolated malignant pericardial effusion is a manifestation of primary cardiac lymphoma (PCL) and primary effusion lymphoma (PEL), rare types of non-Hodgkin's lymphoma (NHL).
  • The diagnosis is based on different cytological methods and analyses including DNA-image cytometry (ICM-DNA).
  • CASE DESCRIPTIONS AND RESULTS: A 75-year-old man and a 66-year-old woman underwent urgent pericardiocentesis for cardiac tamponade due to large pericardial effusion.
  • Although in neither of the two patients systemic chemotherapy was administered, both were free of cancer after a follow-up of ten and nine years respectively.
  • It seems that DNA-aneuploidy may be not absolutely specific for the detection of malignant lymphoid cells in pericardial fluid.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Pericardial Effusion / diagnosis
  • [MeSH-minor] Aged. Aneuploidy. Cardiac Tamponade / etiology. Female. Humans. Image Cytometry. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106328.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Lim ZY, Grace R, Salisbury JR, Creamer D, Jayaprakasam A, Ho AY, Devereux S, Mufti GJ, Pagliuca A: Cardiac presentation of ALK positive anaplastic large cell lymphoma. Eur J Haematol; 2005 Dec;75(6):511-4
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac presentation of ALK positive anaplastic large cell lymphoma.
  • Cardiac involvement as an initial presentation of malignant lymphoma is a rare occurrence.
  • We report the case of an immunocompetent 29-year-old male who presented with syncope and arrythmias secondary to a ventricular cardiac mass.
  • Transcutaneous cardiac biopsy was non-diagnostic, therefore an open cardiac biopsy was performed from which a provisional diagnosis of a cardiac inflammatory pseudotumour was made.
  • Six months after presentation, he developed several subcutaneous lesions with systemic symptoms.
  • Histological and immunophenotypic review of the initial cardiac biopsy revealed features consistent with a diagnosis of CD30, ALK1 positive anaplastic large cell lymphoma (ALCL).
  • Despite intensive treatment with combination chemotherapy, there was significant progression of disease, and he died 11 months after diagnosis.
  • The overall prognosis of cardiac lymphoma remains poor, which may be due to the often late presentation of the tumour.
  • To our knowledge, this is the first reported case of a cardiac ALK positive ALCL.
  • Although rare, cardiac presentation of ALCL should be added to the list of differential diagnoses of cardiac lymphomas.
  • [MeSH-major] Activin Receptors, Type I. Heart Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Activin Receptors, Type II. Adult. Biopsy / methods. Humans. Immunohistochemistry / methods. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313264.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


24. Nakakuki T, Masuoka H, Ishikura K, Seko T, Koyabu S, Tamai T, Sugawa M, Ito M, Nakano T: A case of primary cardiac lymphoma located in the pericardial effusion. Heart Vessels; 2004 Jul;19(4):199-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary cardiac lymphoma located in the pericardial effusion.
  • Primary cardiac lymphoma is a rare disorder with a poor prognosis.
  • We present here a case of 77-year-old woman who was diagnosed as having cardiac lymphoma antemortem according to a cytologic examination of the pericardial effusion.
  • Determination of the levels of serum-soluble interleukin-2 receptor and serum deoxythymidine kinase was useful for the diagnosis.
  • Echocardiography, computed tomography, magnetic resonance imaging, and gallium scan revealed neither lymphadenopathy nor tumor in the heart, so she was diagnosed as having malignant lymphoma that probably originated from the pericardium.
  • Systemic chemotherapy with CHOP (cyclophosphamide, farmorubicin, oncovin, and prednisolone) resulted in a complete resolution of the pericardial effusion.
  • She has been in remission 48 months after discontinuation of the chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma / diagnosis. Pericardial Effusion / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Prednisolone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15278395.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


25. Saotome M, Yoshitomi Y, Kojima S, Kuramochi M: Primary cardiac lymphoma--a case report. Angiology; 2002 Mar-Apr;53(2):239-41
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma--a case report.
  • Primary cardiac lymphoma, which is very rare, is generally regarded to have a poor prognosis.
  • A case of a 69-year-old man with primary cardiac lymphoma diagnosed by antemortem examination is reported.
  • A computed tomography scan of the chest demonstrated a huge right atrial mass with invasion into the other chambers.
  • Cytologic analysis of pericardial effusion revealed diffuse large B-cell type non-Hodgkin malignant lymphoma.
  • The patient died on the 18th day of chemotherapy (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) due to low-output syndrome and multiple organ failure.
  • Although prognosis of primary cardiac lymphoma remains poor, early diagnosis may improve the prognosis.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma / complications
  • [MeSH-minor] Aged. Autopsy. Diagnosis, Differential. Humans. Male. Postmortem Changes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11952118.001).
  • [ISSN] 0003-3197
  • [Journal-full-title] Angiology
  • [ISO-abbreviation] Angiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Jamet B, Saade YA, Torossian F, Bonfils L, Elaerts J: [Cardiac lymphoma disclosed by ischemic accident. A case report]. Ann Cardiol Angeiol (Paris); 2000 Sep;49(6):343-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac lymphoma disclosed by ischemic accident. A case report].
  • [Transliterated title] Lymphome cardiaque révélé par un accident ischémique. A propos d'un cas.
  • We report on the detection of a primitive cardiac lymphoma revealed by a cerebral vascular accident in a context of deterioration of the general state with fever.
  • The diagnosis of the cerebral vascular accident was verified by the brain scan.
  • The echocardiography, in particular the transesophageal ultrasound, suggested the diagnosis of cardiac lymphoma due to the existence of an inhomogeneous multilobar mass invading the right ventricle and largely encompassing the right auricle.
  • The histologic diagnosis of a malignant non-Hodgkin's lymphoma of type B malignancy was confirmed by anatomopathology.
  • The evolution was, unfortunately, rapidly unfavorable, with the patient dying in a state of cerebral suffering despite a combination treatment of chemotherapy and radiotherapy.
  • [MeSH-major] Brain Ischemia / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555345.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Lather N, Islam M, Fergus IV: Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization. Rev Cardiovasc Med; 2008;9(4):275-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization.
  • Tumors involving the heart are rare, and the majority of them are benign.
  • Secondary lymphoma with localization to the heart is the third most common malignant heart tumor and is more common, by far, than primary cardiac lymphomas.
  • In patients with human immunodeficiency virus, the risk of development of systemic lymphoma is 60 to 200 times higher than in the general population.
  • Transthoracic echocardiography is the initial modality of choice for diagnosis of cardiac lymphomas because it is readily available and helps localize the tumor, but transesophageal echocardiography and magnetic resonance imaging remain the best tests for evaluation.
  • Treatment consists primarily of chemotherapy, and anticoagulation can be used in certain cases where embolization of the tumor is likely.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Atria / pathology. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Embolism / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Echocardiography. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed


28. Mioulet D, Braem L, Heno P, Paule P, Peloni JM, Bonnet D, Fourcade L: [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter]. Ann Cardiol Angeiol (Paris); 2009 Apr;58(2):117-21
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter].
  • Primary or secondary cardiac lymphomas are not frequent.
  • Their clinical expression is unusual and the diagnosis is rarely made during the patient's life.
  • Our case report, which is a slow atrial flutter with a pericardial effusion, is an uncommon discovery mode for a malignant lymphoma.
  • Their diagnosis and the mechanism of the arythmia were allowed by non-invasive cardiac imagery (transesophageal echography and magnetic resonance imaging), which showed a tumour-like infiltration of the right atrium, of the right ventricle posterior wall, and of the atrioventricular junction.
  • The diagnosis of a high grade B cell malignant non-hodgkin lymphoma, involving the bone marrow, the liver and the kidneys was made by biopsies of lymph nodes, histological analysis of the bone marrow, and a body CT scan.
  • Throughout the first chemotherapy sequence, we observed a spontaneous return to a sinusal rhythm, and the cardiac MRI showed a regression of the myocardial infiltration and of the pericardial effusion; moreover, the patient's state improved and the peripheral lymph nodes shrank back to a normal size.
  • However, the patient passed away, due to neurological complications 13 months after the diagnosis of lymphoma, without recurrence of cardiac involvement.
  • [MeSH-major] Atrial Flutter / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657797.001).
  • [ISSN] 1768-3181
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Rafajlovski S, Tatić V, Ilić S, Kanjuh V: [Frequency of metastatic tumors in the heart]. Vojnosanit Pregl; 2005 Dec;62(12):915-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frequency of metastatic tumors in the heart].
  • INTRODUCTION: Secondary or metastatic tumors in the heart occur more frequently than primary ones, and, according to the published series, their frequency found in autopsic material ranges from 1.6% to 20.6%.
  • Metastatic tumors in the heart are rarely clinically symptomatic, and, therefore, they are rarely diagnosed within the lifetime.
  • The aim of this study was to analyze the frequency of metastatic tumors of the heart, their primary localization, as well as the localization of the metastases found in the autopsic material within the period 1972-2004.
  • METHODS: During the autopsy of the patients died of metastatic tumors, we microscopically and macroscopically analyzed all the organs and tissues to determine the metastases of primary tumors in other organs, especially in the heart and pericardium.
  • In 2 928 (25.6%) out of 11 403 autopsies, the presence of malignant tumor was diagnosed, and in 79 (2.7%) of these cases, metastasis of the heart was found out.
  • Only in 5 of the cases, the presence of metastasis in the heart was diagnosed during the lifetime.
  • The most frequent metastases in the heart were caused by pulmonary carcinoma (18 cases), leukemia and malignant lymphoma (8 cases, each), then pancreatic and breast carcinoma, while the metastases of other carcinomas were rather rare.
  • CONCLUSION: Metastatic tumors of the heart are rather rare, and rarely clinically symptomatic, and, thus, rarely diagnosed during life.
  • The methods of choice for the diagnosis of the metastasis in the heart are echocardiography, computerized tomography, magnetic resonance imaging, cytological analysis of the pericardial effusion and biopsy.
  • The treatment includes surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16375220.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


30. Nascimento AF, Winters GL, Pinkus GS: Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Am J Surg Pathol; 2007 Sep;31(9):1344-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
  • Primary lymphomas of the heart are rare and frequently are diagnosed at autopsy.
  • Modern imaging technology now permits early diagnosis and treatment.
  • This report describes the clinical, histologic, immunophenotypic, and molecular genetic findings for 5 patients with malignant lymphoma restricted to the cardiac muscle, with or without pericardial involvement.
  • Electrocardiographic changes included junctional rhythm, incomplete right bundle branch block and ST and T waves abnormalities, and ST segment elevation and first-degree atrioventricular block with intermittent complete heart block.
  • In all cases, biopsy or resection of the lesion or cytologic examination of the pericardial fluid established a diagnosis.
  • All tumors were of B-cell phenotype and included 4 cases of large cell lymphoma and one unclassifiable small cell lymphoma.
  • One patient died shortly after diagnosis due to cerebral infarction.
  • Two patients are alive without disease after chemotherapy with CHOP after 120 and 192 months.
  • One patient underwent chemotherapy with CHOP and rituximab, and shows persistent cardiac involvement by lymphoma but with a decrease in tumor burden at 7 months of follow-up.
  • Clinical outcome is variable; however, early diagnosis in conjunction with effective treatment (surgery and/or chemotherapy) may result in an excellent prognosis.
  • Primary cardiac lymphoma should be included in the differential diagnosis of a right atrial mass.
  • [MeSH-major] Antigens, CD / analysis. Gene Expression Regulation, Neoplastic. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gene Rearrangement. Genotype. Heart Atria / pathology. Heart Ventricles / pathology. Humans. Immunophenotyping. Karyotyping. Middle Aged. Pericardium / pathology. Prednisone / administration & dosage. Prednisone / therapeutic use. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721189.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. Ishiguro K, Kojima K, Tsubota M, Seki M, Kurumaya H: [Malignant cardiac lymphoma]. Kyobu Geka; 2000 Mar;53(3):233-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant cardiac lymphoma].
  • The transesophageal echocardiography showed cardiac tumor in the right atrium.
  • It was diagnosed as malignant lymphoma of B-cell type by histological examination.
  • Then he received chemotherapy.
  • It was diagnosed as malignant lymphoma of the same cell type as in the heart.
  • After the chemotherapy (CHOP, 6 cycles), the mass disappeared.
  • [MeSH-major] Heart Neoplasms / surgery. Lymphoma, B-Cell / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Heart Atria. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714114.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Tai CJ, Wang WS, Chung MT, Liu JH, Chiang CY, Yen CC, Fan FS, Chiou TJ, Chen PM: Complete atrio-ventricular block as a major clinical presentation of the primary cardiac lymphoma: a case report. Jpn J Clin Oncol; 2001 May;31(5):217-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete atrio-ventricular block as a major clinical presentation of the primary cardiac lymphoma: a case report.
  • It is uncommon for malignant lymphomas to present primarily with cardiac invasion as the main clinical feature.
  • Cardiac tamponade is another common disease entity which, if it locates over outlets of great vessels, may also exert symptoms of obstructive vessels.
  • Diagnosis can be made by needle aspiration under the guidance of transcutaneous or transesophageal echocardiography.
  • Both CT scan and MRI play positive roles in the diagnosis of cardiac lymphomas, and the latter can even provide much more image information than the former.
  • We report a 70-year-old male with primary cardiac lymphoma with initial clinical pictures of sudden onset of complete atrio-ventricular block.
  • Chemotherapy was utilized with cyclophosphamide, vincristine and prednisolone (COP) initially for four courses and followed by adding doxorubicin (CHOP) for another three courses.
  • The patient was still in remission status after treatment for 2 years.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / complications. Lymphoma / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Electrocardiography. Heart Atria. Humans. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450997.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 19
  •  go-up   go-down


33. Sarjeant JM, Butany J, Cusimano RJ: Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs; 2003;3(6):407-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the heart: epidemiology and management of primary tumors and metastases.
  • Cardiac tumors, benign or malignant, are rare and most are benign.
  • The most common benign tumor is the cardiac myxoma.
  • Malignant cardiac tumors are usually sarcomas.
  • The pericardium can be the site of benign and malignant cardiac tumors, though metastatic tumors occur here far more commonly than do primary tumors.
  • Successful treatment for benign cardiac tumors is usually achieved by surgical resection.
  • Surgery for primary malignant tumors is, however, much less successful as complete resection is usually not possible.
  • Primary cardiac lymphoma may be successfully treated by chemotherapy.
  • Tumors that metastasize to the heart from other organs occur 100- to 1000-fold more commonly than primary cardiac tumors.
  • Metastatic spread to the heart has been identified in approximately one-fifth of all patients who have metastatic cancer with lung carcinoma being the most common primary tumor.
  • Symptoms of cardiac metastases vary, and they depend on the site and extent of the lesions.
  • Treatment varies depending on the pathology of the primary tumor.
  • However, the aim of treatment is usually symptomatic relief.
  • With the advent of AIDS, Kaposi's sarcoma and high grade B cell lymphomas have also been identified in cardiac tissue.
  • The aim of this article is to review the epidemiology, clinical presentation, pathology and treatment of cardiac tumors.
  • [MeSH-major] Heart Neoplasms
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Neoplasm Metastasis. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728061.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 62
  •  go-up   go-down


34. Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, Krailo MD, Termuhlen AM, Morse M, Siegel SE: Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol; 2001 Nov;37(5):432-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.
  • BACKGROUND: Early Children's Cancer Group (CCG) trials indicated that the cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) regimen was superior to the LSA2L2 regimen for non-lymphoblastic (NLB) non-Hodgkin lymphoma (NHL).
  • Studies by other groups suggested that addition of anthracyclines to standard therapies could improve outcome.
  • Patients with CNS or marrow involvement (stage IV) were non-randomly treated with D-COMP (N = 120).
  • RESULTS: Ten-year event-free survival in COMP and D-COMP patients was similar: 55 +/- 4.3% (Estimate +/- SE) vs. 57 +/- 4.2% (not significant).
  • Stage I-III patients with large-cell (LC) NHL had worse 10-year event-free survival (EFS) (48 +/- 4.9%) than those with small non-cleaved cell (SNCC) NHL disease (61 +/- 3.5%, P < 0.05 in multivariate analysis), but equivalent survival (65 +/- 4.7% vs. 63 +/- 3.5%) due to significantly higher salvage rates in LC patients, especially those failing more than 12 months from diagnosis.
  • Addition of daunomycin resulted in higher rates of grade 3/4 hematologic toxicity and stomatitis, as well as late cardiac-related deaths.
  • The incidence of second malignant neoplasms was 1.0% at 10 years.
  • CONCLUSIONS: Addition of daunomycin to standard COMP therapy did not improve outcome in pediatric disseminated NLB NHL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / pharmacology. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Heart Diseases / chemically induced. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Neutropenia / chemically induced. Prednisone / administration & dosage. Recurrence. Stomatitis / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745871.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 02649; United States / NCI NIH HHS / CA / CA 02971; United States / NCI NIH HHS / CA / CA 03526; United States / NCI NIH HHS / CA / CA 03750; United States / NCI NIH HHS / CA / CA 03888; United States / NCI NIH HHS / CA / CA 07306; United States / NCI NIH HHS / CA / CA 07431; United States / NCI NIH HHS / CA / CA 10382; United States / NCI NIH HHS / CA / CA 11796; United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 14560; United States / NCI NIH HHS / CA / CA 17829; United States / NCI NIH HHS / CA / CA 20320; United States / NCI NIH HHS / CA / CA 26044; United States / NCI NIH HHS / CA / CA 26126; United States / NCI NIH HHS / CA / CA 26270; United States / NCI NIH HHS / CA / CA 27678; United States / NCI NIH HHS / CA / CA 28851; United States / NCI NIH HHS / CA / CA 28882; United States / NCI NIH HHS / CA / CA 29013; United States / NCI NIH HHS / CA / CA 29314; United States / NCI NIH HHS / CA / CA 36004; United States / NCI NIH HHS / CA / CA 36015
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; COMP protocol
  •  go-up   go-down


35. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A: Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol; 2002 May;117(2):379-86
Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.
  • The study included 55 patients (18 with non-Hodgkin's lymphoma, 10 with acute lymphoblastic leukaemia, eight with acute myeloid leukaemia, five with chronic myeloid leukaemia, four with chronic lymphocytic leukaemia, four with multiple myeloma, three with myelodysplastic syndrome, two with myelofibrosis and one with thalassemia) who developed PCP.
  • Twelve patients (22%) developed PCP despite protective isolation in a laminar airflow room.
  • Chest radiography or computerized tomography showed interstitial infiltrates in 34 patients (62%), alveolar infiltrates in 12 patients (22%), and alveolar-interstitial infiltrates in nine patients (16%).
  • The diagnosis was made in two patients at autopsy.
  • All patients except one started a specific treatment (52 patients trimethroprim/sulphamethoxazole, one pentamidine and one dapsone).
  • Sixteen patients (29%) died of PCP within 30 d of diagnosis.
  • Multivariate analysis showed that prolonged steroid treatment (P < 0.006) and a radiological picture of diffuse lung involvement (P < 0.003) were negative diagnostic factors.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Anti-Infective Agents / therapeutic use. Bronchoalveolar Lavage Fluid / microbiology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / microbiology. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / microbiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / microbiology. Leukemia, Myeloid / mortality. Lung / radiography. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / microbiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / microbiology. Multiple Myeloma / mortality. Multivariate Analysis. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / microbiology. Myelodysplastic Syndromes / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / microbiology. Primary Myelofibrosis / mortality. Retrospective Studies. Thalassemia / drug therapy. Thalassemia / microbiology. Thalassemia / mortality. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972521.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  •  go-up   go-down


36. Dinić-Uzurov V, Lalosević V, Milosević I, Urosević I, Lalosević D, Popović S: [Current differential diagnosis of hypereosinophilic syndrome]. Med Pregl; 2007 Nov-Dec;60(11-12):581-6
Genetic Alliance. consumer health - Hypereosinophilic syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current differential diagnosis of hypereosinophilic syndrome].
  • REACTIVE EOSINOPHILIA DUE TO INFECTIOUS AND PARASITIC DISEASES: Tissue helminth infections, especially toxocariasis, cause severe and long-standing hypereosinophilia.
  • Despite specific therapy, eosinophilia may persist for over a year after diagnosis, and decreases slowly.
  • HEMATOLOGIC AND OTHER NEOPLASTIC DISEASES: Numerous neoplastic diseases, like Hodgkin's and other malignant lymphomas, myeloproliferative diseases, systemic mastocytosis etc., may be associated with marked eosinophilia.
  • We had two patients with clinical and histological features resembling chronic eosinophilic leukemia, and many others with T-cell lymphoma, planocellular or adenocarcinoma etc. where eosinophilia persisted DRUG-INDUCED EOSINOPHILIA: Drugs associated with eosinophilia include penicillins, tetracyclines, especially minocycline, clarithromycin, tetrazepam, mefloquine, and many, others.
  • Toxins associated with L-tryptophan cause eosinophilia-myalgia syndrome and toxic oil syndrome, also belonging in this group.
  • Treatment includes drug discontinuation and administration of corticosteroids.
  • HYPEREOSINOPHILIA WITH ORGAN DYSFUNCTION: Many severe diseases, such as sarcoidosis, Churg-Strauss syndrome, pemphigus vulgaris, eosinophilic gastrointestinal diseases, inflammatory bowel disease and many others are associated with hypereosinophilia and target organ damage, e.g. involvement of the heart, lungs, skin, or nervous tissue.
  • If the differential diagnosis of hypereosinophilia fails to resolve the etiology succesfully, the diagnosis of idiopathic HES remains.
  • [MeSH-major] Hypereosinophilic Syndrome / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eosinophilia / diagnosis. Eosinophilia / etiology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666600.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


37. Durrleman N, El Hamamsy I, Demaria R, Carrier M, Perrault LP, Albat B: [Is Dacron carcinogenic? Apropos of a case and review of the literature]. Arch Mal Coeur Vaiss; 2004 Mar;97(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant cardiac tumours are extremely rare.
  • The authors report a case of primary cardiac lymphoma nine years after implantation of a double leaflet mitral valve prosthesis.
  • Malignant lymphoma is a haematological form of sarcoma.
  • It typically presents as a nodular or diffuse myocardial infiltrate explaining its clinical expression as cardiac failure and atrioventricular block.
  • Survival after "pure" medical therapy (chemotherapy alone or associated with radiotherapy) is 6 to 8 months after diagnosis.
  • Dacron has been implicated in the pathogenesis of primary cardiac sarcoma.
  • In conclusion, although primary cardiac lymphoma is a rare condition, it should be considered, as with thrombosis, a possible differential diagnosis of acute dysfunction of cardiac valvular prostheses.
  • [MeSH-major] Heart Neoplasms / etiology. Heart Valve Prosthesis / adverse effects. Lymphoma, Large-Cell, Immunoblastic / etiology. Polyethylene Terephthalates / adverse effects
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asthenia / etiology. Diagnostic Errors. Fatal Outcome. Female. Humans. Mitral Valve / surgery. Multiple Organ Failure / etiology. Myxoma / diagnosis. Sarcoma / chemically induced. Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106752.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates
  • [Number-of-references] 10
  •  go-up   go-down


38. Riberi A, Gariboldi V, Grisoli D, Collart F: [Cardiac tumors]. Rev Pneumol Clin; 2010 Feb;66(1):95-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tumors].
  • Primary cardiac tumor is a rare disease, with an incidence ranging from 0.001 to 0.03%.
  • Primary malignant tumors of heart are in 95% of cases sarcomas, the remaining 5% are lymphomas.
  • Cardiac's metastases are more frequent than primary tumors.
  • Diagnosis is made by echocardiography TAC and MRI.
  • Whereas surgery is indicated in patients with benign tumors, or localised sarcomas, chemotherapy in those with widespread disease and radiotherapy and chemotherapy in lymphoma.
  • Prognosis is excellent in benign cardiac tumor.
  • Mean survival for sarcomas is 11 months, and lymphoma 5 years.
  • [MeSH-major] Heart Neoplasms / secondary. Heart Neoplasms / surgery
  • [MeSH-minor] Angiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Echocardiography. Humans. Magnetic Resonance Imaging. Myocardium / pathology. Myxoma / diagnosis. Myxoma / pathology. Myxoma / surgery. Prognosis. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Masson SAS.
  • (PMID = 20207301.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 28
  •  go-up   go-down


39. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis; 2010 Sep-Oct;53(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a considerable number of patients with breast or lung cancer or with mediastinal lymphoma, in addition to direct involvement by the tumor, radiation therapy as well as systemic tumor treatment can also lead to pericardial effusion.
  • To distinguish between these 3 different conditions leading to pericardial effusion, the diagnosis should be based on pericardiocentesis followed by fluid analysis for cytology and biomarkers, on epicardial and pericardial biopsy facilitated by flexible pericardioscopy with analysis of specimens by conventional histology and molecular biology techniques for viral and microbial aetiology.
  • With these methods, 42 patients demonstrated malignant effusion, 15 patients had radiation-induced pericardial, effusion, and in 11 patients without radiation therapy, the effusion could be attributed to either viral infection in 5 cases or to an autoimmune process in the remaining 6 patients.
  • Consequently, intrapericardial treatment could be tailored for each cohort: neoplastic effusion was treated with intrapericardial cisplatin (single instillation of 30 mg/m(2) per 24 hours); in addition to the tumor-specific systemic chemotherapy, intrapericardial triamcinolone acetate (Volon A) was given in a dose of 500 mg/m(2) in the patients with autoimmune and radiation-induced effusion.
  • Saline rinsing and intrapericardial sclerosing treatment were the treatment of choice in viral pericardial effusion.
  • Oral colchicine treatment (2-3 x 0.5 mg) was given in all patients for at least 3 months.
  • This differential diagnostic approach and the results of treatment were compared with published series.
  • [MeSH-major] Neoplasms / therapy. Pericardial Effusion / diagnosis. Pericardial Effusion / therapy. Radiation Injuries / diagnosis. Radiation Injuries / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Biomarkers / analysis. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pericardiocentesis. Polymerase Chain Reaction. Predictive Value of Tests. Radiotherapy / adverse effects. Recurrence. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20728703.001).
  • [ISSN] 1873-1740
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


40. Tichelli A, Bhatia S, Socié G: Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol; 2008 Jul;142(1):11-26
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation.
  • Haematopoietic stem cell transplantation (HCT) is the treatment of choice for defined malignant and non-malignant haematological disorders.
  • In comparison with other post-transplant complications, cardiac or cardiovascular consequences seem to occur at a much lower frequency.
  • Early complications are usually associated with patient history before transplantation, primary diagnosis, age of the patient and associated comorbidities, and the type of transplantation and conditioning used.
  • Late cardiac and cardiovascular events may occur years and even decades after HCT, and are related to cardiotoxic chemotherapy, mediastinal radiation therapy, gender, age at transplantation, cardiovascular risk factors and graft-versus-host disease in allogeneic HCT.
  • As has been observed in long-term survivors of Hodgkin lymphoma, where the incidence of cardiovascular complications emerged as a significant problem with increasing follow-up, it is anticipated that the incidence of these complications after HCT will also increase significantly with increasing follow-up of the survivors.
  • This review presents the available data on early and late cardiac and cardiovascular consequences after HCT, and presents recommendations for cardiac assessment and management of these complications.
  • [MeSH-minor] Age Factors. Amyloidosis / etiology. Anthracyclines / adverse effects. Graft vs Host Disease / etiology. Heart Diseases / etiology. Heart Diseases / prevention & control. Hematopoietic Stem Cell Mobilization / adverse effects. Humans. Radiotherapy / adverse effects. Risk Factors. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430191.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 30206
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Number-of-references] 130
  •  go-up   go-down


41. Memon AQ, Xavier L: Malignant lymphoma of the heart. Featured echocardiogram and case report. Cardiol Rev; 2002 Nov-Dec;10(6):323-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the heart. Featured echocardiogram and case report.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Echocardiography / methods. Humans. Male. Prednisone / therapeutic use. Ventricular Dysfunction, Left / diagnosis. Ventricular Dysfunction, Left / drug therapy. Ventricular Dysfunction, Left / ultrasonography. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12390686.001).
  • [ISSN] 1061-5377
  • [Journal-full-title] Cardiology in review
  • [ISO-abbreviation] Cardiol Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement